Mediaboss Marketing

The Home Office has privately predicted a further sharp rise in legal migration, with an influx of over a million foreign workers and students projected in 2024.

Also hotly debated by Telegraph readers this week was Britain pledging to send Ukraine custom-built suicide drones to further support the countrys efforts against Russia and Suzanne Moore writing on the real reason the birth rate is dropping.

Read on to see how readers contributed to the conversation in the comments section and via the Front Page newsletter.

The Telegraph revealed that an official document sent by the Home Office to Downing Street last year warned that there will be a further sharp rise in immigration by the next election, unless ministers take action. This came after Suella Braverman, the Home Secretary, stated on Monday that an unchecked drive towards multiculturalism without successful integration is a recipe for disaster.

Readers shared their indignation in the comments section and blamed the Conservative Party for failing to get immigration levels under control.

Excerpt from:
'Losing control of the borders is the most serious breach of duty a ... - The Telegraph

A University of Victoria-led project on Wednesday revealed worsening alcohol policy grades across the country and proposed detailed steps to get Canada back on track.

News of alcohols harms and costs has dominated headlines post-COVID. The Canadian Alcohol Policy Evaluation (CAPE) Project, led by UVics Canadian Institute for Substance Use Research (CISUR), brought together researchers from institutions across Canada to evaluate alcohol control policies federally and in all 13 provinces and territories. Today, they release their results alongside evidence-based solutions to improve health and well-being.

This is about more than asking individuals to consider cutting down on their drinking. Yes, that can be important, but governments need to make changes to the broader drinking environment. CAPE offers a scientific evaluation of where our governments are at in terms of health-oriented alcohol policy, while also giving the tools they need to improve.

Dr. Tim Naimi, CISUR director and lead of the CAPE Project

While the project offers a less than rosy picture of where government alcohol policy sits today, it comes with solutions. CAPE has prepared a detailed report card for each of the provinces and territories and the federal government, which shows them how they are faring in 11 different policy domains including pricing and taxation, physical availability, control system, marketing and advertising, health and safety messaging and more. It offers tailored recommendations for how they can improve their scores and strengthen their policies in support of public health.

Some of these recommendations include creating minimum prices tied to alcohol content and indexed to inflation, moving the oversight of alcohol regulation and sales to a government ministry focused on health or safety rather than finance, reducing hours of sale, mandating warning labels for alcohol containers or officially endorsing the new Canadian Guidance on Alcohol and Health, explains Naimi. Governments could also develop an alcohol strategy on a provincial or territorial level or create a federal Alcohol Act.

Many of these strong policies are in place in some parts of Canada today. If governments were to implement the best existing policies consistently across Canadas provinces and territories, they could score 80 per cent or an A-.

The Canadian Alcohol Policy Evaluation (CAPE) looked at how well Canadas provinces and territories are implementing alcohol policies with strong evidence for protection of public health and safety.

This is the CAPE Projects third evaluation of alcohol policy across Canadas provincial, territorial and federal governmentsand the results arent great. Every single jurisdiction got an overall failing grade, with the lowest scoring jurisdiction, Northwest Territories, only getting 32%. The highest-scoring jurisdictionsManitoba and Quebeconly scored 44% and 42%, respectively. The federal governments score was just 37%.

This reflects red tape reduction, modernizing initiatives and other erosions of public-health-focused alcohol policies we have seen in recent years, says Naimi. We were starting to see it ramp up when we released our last evaluation in 2019, and during the COVID-19 pandemic we have only seen it get worse.

The CAPE Project is a collaborative project involving researchers from the Centre for Addiction and Mental Health (CAMH), Western University, St Francis Xavier University, Dalhousie University, and the Canadian Institute for Health Information. The institutions worked together to create the evidence-based scoring rubric, collect relevant policy data from across the country, and score the individual provincial, territorial and federal governments on how they fared across the 11 different policy domains. The project also relied on stakeholders withinthe government to validate the data and ensure its accuracy.

This was a massive, scientifically rigorous project that could only be achieved via these strong partnerships with institutions and governments across Canada, says Norman Giesbrecht, scientist emeritus at CAMHs Institute for Mental Health Policy Research who has been a key part of CAPE since its first iteration. We are grateful to be able to do this evaluation for a third time and build on the excellent work that began with the first CAPE in 2011.

The CAPE Project was funded by Health Canada and the Public Health Agency of Canada.

For more details on the project, visitalcoholpolicy.cisur.ca.

A media kit containing infographics detailing overall provincial, territorial and federal scores, details and recommendations by provincial, territorial and federal governments is available viaDropbox.

-- 30 --

Amanda Farrell-Low (Communications Officer, CISUR) at 250-472-5445 or farlow@uvic.ca

Go here to see the original:
Steps to Repair Canada's Alcohol Policy - University of Victoria

Attorney-General and Minister for Justice, Minister for Women and Minister for the Prevention of Domestic and Family ViolenceThe Honourable Shannon Fentiman

This week, Australias legal sector comes together for Law Week 2023, and to raise awareness about how we can all take part in combating coercive control.

Throughout Law Week, a range of community activities will be hosted, showcasing the importance of the legal system for all legal professions, students considering a career in law, and the public.

Law Week 2023 will also promote ways the community can help address the patterned nature of coercive control and better protect those at risk and understand new laws being introduced.

The message is important but simple it is everyones responsibility to understand the many elements of domestic and family violence (DFV), including coercive control, and support is available for those impacted.

It aligns with the ongoing work of the Queensland Government to end DFV and coercive control, including the introduction of a standalone offence criminalising coercive control later this year.

Those attending Law Week 2023 activities are encouraged to learn more about Queenslands new laws and how the community can continue to support those at risk of DFV.

For more information and support, visit https://www.qld.gov.au/law/law-week and http://www.qld.gov.au/domesticviolence.

Quotes attributable to the Attorney-General and Minister for Justice, Shannon Fentiman:

Law Week is an incredible opportunity to bring the legal sector together, while educating Queenslanders about the importance of new laws.

I encourage all Queenslanders, and especially students who are considering a career in the law, to learn more about the many components of our legal system during Law Week.

Thats why were promoting the warning signs of coercive control, and how individuals, communities, and workplaces can help to end domestic and family violence.

This is also an important reminder to victims impacted by all forms of domestic and family violence services are available that can offer support as well as practical advice and assistance.

ENDS

Media contact Natarjsha Kramer 0456 436 934

Go here to see the original:
Law Week raises awareness of how everyone can combat coercive ... - Media Statements

NORTH CHICAGO, Ill., May 19, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved EPKINLYTM (epcoritamab-bysp), as the first and only T-cell engaging bispecific antibody for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS), including DLBCL arising from indolent lymphoma, and high-grade Bcell lymphoma (HGBL), after two or more lines of systemic therapies.EPKINLY is approved under the FDA's Accelerated Approval program based on response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. EPKINLY is being co-developed by AbbVie and Genmab as part of the companies' oncology collaboration.

DLBCL is a type of aggressive, fast-growing non-Hodgkin's lymphoma (NHL), a cancer that develops in the lymphatic system and affects B cells, a type of white blood cell. DLBCL is the most common type of NHL, comprising of an estimated 30,400 U.S. cases in 2022 and 150,000 new cases each year globally. DLBCL patients are typically treated with chemoimmunotherapy-based regimens. For R/R patients, several targeted therapies including T-cell mediated treatments have recently emerged. However, single agent and ready-available or off-the-shelf treatment options are limited.1,2,3,4,5

"DLBCL is an aggressive cancer type that can rapidly progress and resist treatment. The FDA approval of EPKINLY represents a new treatment mechanism of action for third line DLBCL patients. As a non-chemotherapy, single-agent treatment for DLBCL patients, we hope that EPKINLY can effectively treat this aggressive cancer type and can be used for patient care quickly and in an off the shelf form for physicians," said Thomas Hudson, M.D., senior vice president, research and development, chief scientific officer, AbbVie. "The approval is just the first step, with our partner Genmab, towards a shared goal of developing a core therapy for patients with B-cell malignances."

AbbVie is committed to transforming standards of care across blood cancers and advancing a dynamic cancer research and treatment pipeline. EPKINLY marks the third approved blood cancer treatment available as part of AbbVie's growing oncology portfolio, aswe strive to make a remarkable impact for people living with cancer.

"Patients with DLBCL who relapse or are refractory to currently available therapies have limited options. Generally, the prognosis for these patients is poor and management of this aggressive disease can be challenging," said Tycel Phillips, M.D., City of Hope Associate Professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation. "Epcoritamab is a subcutaneous bispecific antibody that offers an additional treatment option for this patient population. With this approval, patients who are in need of additional therapy may have the opportunity to receive epcoritamab after failure to respond or relapse after two or more systemic therapies."

"The FDA approval of EPKINLY represents a new treatment for diffuse large B-cell lymphomas among patients who have relapsed or have refractory disease and are looking for a new medication," said Meghan Gutierrez, chief executive officer, Lymphoma Research Foundation.

Highlights of the Phase 1/2 EPCORE NHL-1 clinical trial supporting the approval:

About EPKINLYTM (epcoritamab-bysp)EPKINLY is a prescription medicine used to treat adults with certain types of diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that has come back (relapsed) or that did not respond to previous treatment (refractory), and who have received 2 or more treatments for their cancer. EPKINLY is approved based on patient response data. A study is ongoing to confirm the clinical benefit of EPKINLY. It is not known if EPKINLY is safe and effective in children.

EPKINLY is an IgG1-bispecific antibody created using Genmab's proprietary DuoBody technology. Genmab's DuoBody-CD3 technology is designed to direct cytotoxic T cells selectively to elicit an immune response towards target cell types. It is designed to simultaneously bind to CD3 on T cells and CD20 on B-cells and induces T cell mediated killing of CD20+ cells.5,6,7

AbbVie and Genmab are evaluating EPKINLY as a monotherapy, and in combination, across multiple lines of therapy in a range of hematologic malignancies. This includes an ongoing Phase 3, open-label, randomized controlled trial evaluating EPKINLY as a monotherapy in patients with R/R DLBCL (NCT: 04628494) and two Phase 3, open-label, randomized controlled trials evaluating EPKINLY combination regimens in patients with newly diagnosed DLBCL (NCT: 05660967) and R/R follicular lymphoma (NCT: 05409066). The companies will share commercial responsibilities in the U.S. and Japan, with AbbVie responsible for further global commercialization.AbbVie will continue to pursue regulatory submissions for epcoritamab across international markets throughout the year.

IMPORTANT SAFETY INFORMATION

Important WarningsEPKINLY can cause serious side effects, including:

Due to the risk of CRS, you will receive EPKINLY on a "step-up" dosing schedule. The step-up dosing schedule is when you receive smaller "step-up" doses of EPKINLY on day 1 and day 8 of your first cycle of treatment (cycle 1). You will receive your first full dose of EPKINLY on day 15 of cycle 1. If your dose of EPKINLY is delayed for any reason, you may need to repeat the step-up dosing schedule. Before each dose in cycle 1, you will receive medicines to help reduce your risk of CRS. Your healthcare provider will decide if you need to receive medicine to help reduce your risk of CRS with future cycles.

Due to the risk of CRS and neurologic problems, you should be hospitalized for 24 hours after receiving your first full dose of EPKINLY on day 15 of cycle 1. Your healthcare provider will monitor you for symptoms of CRS and neurologic problems during treatment with EPKINLY, as well as other side effects, and treat you if needed. Your healthcare provider may temporarily stop or completely stop your treatment with EPKINLY if you develop CRS, neurologic problems, or any other side effects that are severe.

Do not drive or use heavy or potentially dangerous machinery if you develop dizziness, confusion, tremors, drowsiness, or any other symptoms that impair consciousness until your symptoms go away. These may be symptoms of CRS or neurologic problems.

EPKINLY can also cause other serious side effects, including:

Your healthcare provider may temporarily stop or completely stop treatment with EPKINLY if you develop certain side effects.

Before you receive EPKINLY, tell your healthcare provider about all of your medical conditions, including if you:

Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

The most common side effects of EPKINLY include CRS, tiredness, muscle and bone pain, injection site reactions, fever, stomach-area (abdominal) pain, nausea, and diarrhea.

These are not all the possible side effects of EPKINLY. Call your doctor for medical advice about side effects.

You are encouraged to report side effects to the FDA at (800) FDA-1088 or http://www.fda.gov/medwatchor to GenmabUS, Inc. at 1-855-4GENMAB (1-855-443-6622).

Please see Medication Guide, including Important Warnings.

About AbbVie in OncologyAt AbbVie, we are committed to transforming standards of care for multiple blood cancers while advancing a dynamic pipeline of investigational therapies across a range of cancer types. Our dedicated and experienced team joins forces with innovative partners to accelerate the delivery of potentially breakthrough medicines. We are evaluating more than 20 investigational medicines in over 300 clinical trials across some of the world's most widespread and debilitating cancers. As we work to have a remarkable impact on people's lives, we are committed to exploring solutions to help patients obtain access to our cancer medicines. For more information, please visithttp://www.abbvie.com/oncologyand ourBlood Cancer Press Kit page.

About AbbVieAbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology and gastroenterology, in addition to products and services across our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at http://www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn.

Forward-Looking StatementsSome statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2022 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

1 Sehn LH, Salles G. N Engl J Med. 2021;384:842-858.2 What is Lymphoma. Lymphoma Coalition. https://lymphomacoalition.org/what-is-lymphoma/. Accessed April 24, 2023.3 Kanas G, Ge W, Quek RGW, et al. Leukemia & Lymphoma. 2022;63(1):54-63.4 Crump M, Neelapu SS, Farooq U, et al. Blood. 2017;130(16):1800-1808.5 Chao MP. Cancer Manag Res. 2013;5:251-269.6 Engelberts PJ, Hiemstra IH, de Jong B, et al. "DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing." EBioMedicine. 2020;52:102625. DOI: 10.1016/j.ebiom.2019.1026257 Rafiq S, Butchar JP, Cheney C, et al. "Comparative Assessment of Clinically Utilized CD20-Directed Antibodies in Chronic Lymphocytic Leukemia Cells Reveals Divergent NK Cell, Monocyte, and Macrophage Properties." J. Immunol. 2013;190(6):2702-2711. DOI: 10.4049/jimmunol.12025888 Singh V, Gupta D, Almasan A."Development of Novel Anti-Cd20 Monoclonal Antibodies and Modulation in Cd20 Levels on Cell Surface: Looking to Improve Immunotherapy Response." J Cancer Sci Ther. 2015;7(11):347-358. DOI: 10.4172/1948-5956.1000373

SOURCE AbbVie

Continue reading here:
EPKINLY (epcoritamab-bysp) Approved by U.S. FDA as the First ... - AbbVie

May 19, 2023

Its a small program that attracts international students to the University of Manitoba and has an outsized influence on the art scene in Winnipeg, Manitoba and Canada. From May 23 June 23, the five artists graduating from the School of Arts Master of Fine Arts program are set to show their work at the 2023 MFA Thesis Exhibition.

The show includes work from each of the MFA candidates Hamideh Behgar, Timothy Brown, Sonny Cai, Ashkan Nejadebrahimi, and Niki Saghar who have designed their own installations, after receiving professional training in curatorial practices and exhibition design last fall in a week-long workshop with curators Rodney Latourelle and Louise Witthoefft from Berlin, specialists in exhibition installation, public art, colour and light concepts.

It will be an eclectic mix of works ranging from video and performance, through sculpture to drawing, says, Oliver Botar, associate director, graduate studies and research at the School of Art.

Three out of five of the students are originally from Iran, and a theme of displacement runs through the works, he says.

Botar encourages people to come out. He points to the calibre of artists who have graduated from the MFA program over the last 12 years of its history.

The School of Art has produced a long roster of artists that have gone on to local, national and indeed international fame, including a goodly list of international art stars, some of whom continue to live here, and others whove gone on to major careers in larger Canadian art centres such as Toronto, Montreal and Vancouver, but also to New York, Chicago and Berlin, says Botar. In other words, through our graduates and our network, we are an art school that is present way beyond our borders.

As a female artist who grew up in an environment full of restrictive societal norms, Hamideh Behgar experienced many boundaries, limitations, and high expectations. Through her artistic journey, she has explored the societal pressure to achieve perfection, despite the inherent imperfections that exist in the natural world beyond our control. Her current artistic practice is inspired by childhood imagination and the importance of free play and play sculptures.

Timothy BrownProcessor 1 (still), 2022videoImage courtesy of the artist

Wavesis a temporal conversation taking place across a variety of media, in which Timothy Brown addresses the grief and trauma from the loss of his mother while also re-examining his identity in relation to the birth of his son. The exhibition utilizes audio, video, installation, drawing, and text whilealso inviting the viewer into the exhibition space as a participant. WithWaves, history, lineage, identity, grief, trauma, control, and emotion collide, re-examining the relationship between viewer, artist, and artwork.

Sonny CaiImage courtesy of the artist

The exhibition title,Three Begat All Things, comes from the description of Yinyang in Tao Te Ching: the existence of the laws of Yinyang, the human understanding of these laws, and the physical manifestation of these laws. These three concepts come together to form Tao and produce all things. The direct translation of Yinyang from Chinese to English is Sun and Shadow, which is perfectly embodied within Sonny Cais choice of medium: The seriesThree Begat All Thingsuses Cyanotype techniques creating a beautiful blue visual effect in accordance with the sun and its shadows.

Ashkan NejadebrahimiImmersion I, 2023Mixed media (wire, wood, clear acrylic sheets, ink, spray paint), 70 x 70 x 35 cmImage courtesy of the artist

Ashkan Nejadebrahimi makes abstract drawings on 2D surfaces and sometimes the lines he draws move into three-dimensional space, taking on sculptural qualities. Drawing for him is an act of probing what is going on inside and around him. He employs Surrealist Automatist techniques, which allow him to suppress conscious control over the creative process. Ashkans work researches the interactions between Self and Other in psychological and social senses, and in his studio, subjects such as monsters, the unconscious, and the quality of non-finito, that is unfinishedness, meet on the ground of drawing.

Niki SaghariImage courtesy of the artist

Niki Saghari is an Iranian multidisciplinary artist currently based in Canada. Her work encompasses photography, performance, video, sound, and installations. She aims to draw attention to the seemingly mundane aspects of daily life and transform them into works that challenge our preconceptions. Through her art, she explores the complexities of human relationships and identity, as well as the passage of time and the impermanence of all things. By revealing the unconscious and exposing our shared experiences, Saghari aims to promote empathy and understanding between people from different cultures and backgrounds. Saghari will be presenting a performance as part of her thesis show at 6PM.

May 23-June 23School of Art Gallery

Opening reception: May 26; 5 8 p.m.

Botar notes that the School of Art and the MFA program have a lot to offer the city and the province. The School of Art is the only art school with a graduate program between Regina/Saskatoon and Toronto/London, and there is no such program in North Dakota or Northern Minnesota. This points to high demand for the graduate program.

With the establishment of our MFA Program some 12 years ago, we also began to attract a good number of international students from countries such as Iran, China, Korea and Latin America (among others), that has helped internationalize our art scene.

Enrolment numbers have been kept small despite the demand says Botar, running to an intake of about five per year for the competitive program which typically see 85 applicants per year. Students accepted to the program get a large studio, receive personalized instruction in small groups from an outstanding roster of faculty, and their degree culminates in a professional MFA thesis show that includes a hard-cover publication of the exhibition.

And the program is growing. We have just doubled our potential intake to 10 due to the demand, which will ensure a larger, more dynamic cohort of students, something that is beneficial for artists at the start of their careers, says Botar. The newly established MA Program in Art and Architectural History (beginning Fall 2023) will further increase the annual cohort by two for the time being.

That personalized instruction, along with outstanding production facilities and full technical support in the award-winning ARTlab are large draws for the program, along with numerous professional development opportunities including workshops, studio visits from top curators, artists and journal editors, says Botar.

We also currently have an artist-in-residence, Prof. Emeritus Erwin Huebner (Biology), who offers one-on-one instruction in scientific imaging techniques and art making to my knowledge the only such instruction and facility in an art school in the country, says Botar.

Without this art school, that was founded together with the Winnipeg Art Gallery in 1912, Winnipeg would not be the cultural centre that it is. Our graduates are the foundation of a complex and rich art scene in Winnipeg, including not only the WAG-Quamajuq, but also many artist-run centres in the fine arts, including video/moving image, installation, printmaking, craft, ceramics, and more.

UM Today Staff

Link:
UM Today | School of Art | It's time for the 2023 MFA Thesis Exhibition - UM Today